康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300601 康泰生物

已收盘 09-24 15:00:00

{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":12.88,"timestamp":1790233431000,"preClose":13.18,"halted":0,"volume":19248798,"delay":0,"changeRate":-0.0228,"floatShares":900000000,"shares":1117000000,"eps":0.0745,"marketStatus":"已收盘","change":-0.3,"latestTime":"09-24 15:00:00","open":13.14,"high":13.24,"low":12.83,"amount":249000000,"amplitude":0.0311,"askPrice":12.88,"askSize":57,"bidPrice":12.87,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.0745,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.18,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":14.5,"lowLimit":11.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116930267,"isCdr":false,"pbRate":1.61,"roa":"--","peRate":172.885906,"roe":"0.52%","epsLYR":0.06,"committee":0.172695,"marketValue":14386000000,"turnoverRate":0.0214,"status":1,"floatMarketCap":11597000000},"requestUrl":"/m/hq/s/300601/wiki","defaultTab":"wiki","newsList":[{"id":"2669159289","title":"9月21日康泰生物涨6.91%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159289?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:46","pubTimestamp":1789980404,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日康泰生物涨6.91%，收盘报12.99元，换手率4.49%，成交量40.44万手，成交额5.17亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6374，较上一交易日上涨2.11%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239","562860"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159211","title":"康泰生物涨6.91%，东海证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159211?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:46","pubTimestamp":1789980390,"startTime":"0","endTime":"0","summary":"今日康泰生物涨6.91%，收盘报12.99元。2026年9月11日，东海证券研究员杜永宏发布了对康泰生物的研报《公司简评报告：积极拓展国内外市场，研发顺利推进》，该研报对康泰生物给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国投证券的冯俊曦、李奔。康泰生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667640866","title":"康泰生物(300601.SZ)总裁苗向拟减持不超47.1万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667640866","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667640866?lang=zh_cn&edition=full","pubTime":"2026-09-15 21:12","pubTimestamp":1789477977,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布公告，公司董事、总裁苗向先生持有公司股份188.47万股(占公司总股本比例0.17%)，计划自公告披露之日起十五个交易日后的三个月内(法律法规、规范性文件规定不得进行减持的时间除外)，以集中竞价或大宗交易的方式减持公司股份不超过47.1万股(即不超过公司总股本比例0.04%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0201","BK0046","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666255305","title":"东海证券：给予康泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2666255305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666255305?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:12","pubTimestamp":1789121549,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏近期对康泰生物进行研究并发布了研究报告《公司简评报告：积极拓展国内外市场，研发顺利推进》，给予康泰生物买入评级。公司业绩逐渐企稳，基本符合预期，报告期末持有现金约33.72亿元，现金流充沛。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为17.32。本文数据来源于东海证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100039672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662141147","title":"康泰生物：8月25日董事刘建凯减持股份合计5.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662141147","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662141147?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:01","pubTimestamp":1787749286,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月26日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年8月25日公司董事,高管刘建凯共减持公司股份5.5万股，占公司总股本为0.0049%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1733.58万，融资余额增加；融券净流入9.95万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600048970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737633","title":"康泰生物：8月24日董事刘建凯减持股份合计5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737633","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662737633?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:01","pubTimestamp":1787662873,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月25日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年8月24日公司董事,高管刘建凯共减持公司股份5.0万股，占公司总股本为0.0045%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入2217.99万，融资余额增加；融券净流入8.1万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500047646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212616","title":"康泰生物（300601）2026年中报简析：净利润同比增长34.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212616?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:15","pubTimestamp":1787436927,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期康泰生物发布2026年中报。根据财报显示，康泰生物净利润同比增长34.25%。截至本报告期末，公司营业总收入12.73亿元，同比下降8.55%，归母净利润5038.61万元，同比上升34.25%。所得税费用变动幅度为83.03%,原因:本报告期利润增加。持有康泰生物最多的基金为疫苗ETF嘉实，目前规模为2.13亿元，最新净值0.6919，较上一交易日下跌2.97%，近一年上涨13.79%。本文数据来源于康泰生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300002031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661162432","title":"康泰生物(300601)6月30日股东户数6.09万户，较上期减少1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661162432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661162432?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:09","pubTimestamp":1787389790,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康泰生物披露，截至2026年6月30日公司股东户数为6.09万户，较3月31日减少1043.0户，减幅为1.68%。在生物制品行业个股中，康泰生物股东户数高于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年3月31日至2026年6月30日，康泰生物区间跌幅为18.27%，在此期间股东户数减少1043.0户，减幅为1.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200015093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661429361","title":"康泰生物最新公告：上半年净利润同比增长34.25%拟10派0.27元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661429361","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661429361?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:10","pubTimestamp":1787317830,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)发布2026年半年度报告，实现营业收入12.73亿元，同比下降8.55%；归属于上市公司股东的净利润5038.61万元，同比增长34.25%。业绩增长主要系公司推进精细化管理和降本增效，运营效率持续提升。公司拟向全体股东每10股派发现金红利0.27元(含税)。注：公司Q2净利润0.17亿，Q1净利润0.33亿，据此计算，Q2净利润环比下降48%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100043656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661652772","title":"8月21日康泰生物跌9.95%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661652772","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661652772?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:46","pubTimestamp":1787302009,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日康泰生物跌9.95%，收盘报13.03元，换手率9.15%，成交量82.38万手，成交额10.81亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.7131，较上一交易日上涨9.0%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","562860","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402706","title":"8月20日康泰生物创60日新高，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402706?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:43","pubTimestamp":1787215393,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日康泰生物涨19.98%创60日新高，收盘报14.47元，换手率11.36%，成交量102.27万手，成交额14.48亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6542，较上一交易日下跌2.74%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","562860","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616948","title":"8月7日康泰生物涨5.07%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616948","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616948?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:49","pubTimestamp":1786092547,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日康泰生物涨5.07%，收盘报12.85元，换手率2.97%，成交量26.78万手，成交额3.36亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6266，较上一交易日下跌1.12%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657878654","title":"股市必读：康泰生物新发布《第八届董事会第十一次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657878654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657878654?lang=zh_cn&edition=full","pubTime":"2026-08-07 02:35","pubTimestamp":1786041312,"startTime":"0","endTime":"0","summary":"公司公告汇总第八届董事会第十一次会议决议公告深圳康泰生物制品股份有限公司第八届董事会第十一次会议审议通过《关于董事会提议向下修正“康泰转2”转股价格及承诺未来期间不再提议向下修正转股价格的议案》。董事会提议下修转股价格，并提交股东大会审议；修正后价格不低于股东大会召开日前二十个交易日及前一交易日公司股票交易均价的较高者。议案尚需股东大会审议，持有本次可转债的股东应回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700002220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631030","title":"康泰生物：全球首创双载体13价肺炎球菌多糖结合疫苗通过拉美、北非国家药监GMP检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657631030?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:52","pubTimestamp":1786020731,"startTime":"0","endTime":"0","summary":"2026年2月，公司全球首创双载体13价肺炎球菌多糖结合疫苗顺利通过拉美、北非国家药监GMP检查，充分验证了公司产品的生产设施、工艺流程、质量管控体系均符合该区域严格的药品生产质量管理规范，标志着产品已具备对应区域市场准入资质，为后续海外市场拓展、深化全球化战略落地奠定了坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600037602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523389","title":"康泰生物（300601）披露关于向下修正‘康泰转2’转股价格的议案，8月5日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523389","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523389?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:20","pubTimestamp":1785939630,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，康泰生物报收于12.48元，较前一交易日上涨0.16%，最新总市值为139.39亿元。该股当日开盘12.42元，最高12.58元，最低12.37元，成交额达1.32亿元，换手率为1.17%。近日，深圳康泰生物制品股份有限公司发布《关于召开2026年第一次临时股东会的通知》，宣布将于2026年8月21日召开2026年第一次临时股东会。会议将审议《关于董事会提议向下修正“康泰转2”转股价格及承诺未来期间不再提议向下修正转股价格的议案》。股权登记日为2026年8月18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612547","title":"康泰生物：8月4日董事刘建凯减持股份合计1.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612547","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657612547?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:01","pubTimestamp":1785934883,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月5日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年8月4日公司董事,高管刘建凯共减持公司股份1.5万股，占公司总股本为0.0013%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出765.02万，融资余额减少；融券净流入5.72万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657764548","title":"康泰生物：公司专门设立了mRNA及新型佐剂的研发团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2657764548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657764548?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:22","pubTimestamp":1785925348,"startTime":"0","endTime":"0","summary":"公司十分重视疫苗新技术路径的应用研究和新技术平台的建立，包括mRNA技术、病毒载体技术、新佐剂技术等。公司专门设立了mRNA及新型佐剂的研发团队，目前mRNA技术路径主要聚焦于RSV、带状疱疹疫苗等产品的开发，佐剂方面主要服务于公司在研管线中重组技术路径的在研产品，除了自主建设技术平台外，公司也持续加强对外合作，积极探索行业未来发展的方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548991","title":"康泰生物：公司积极推动五联苗Ⅲ期临床试验进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657548991?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:18","pubTimestamp":1785925086,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物(300601)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司5联苗什么时候出临床结果，康泰生物回复：您好，公司积极推动五联苗Ⅲ期临床试验进程，目前已完成受试者入组，后续如产品研发及注册进展达到信息披露标准，公司将会根据相关法律法规的规定履行信息披露义务。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500034031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371716","title":"康泰生物：7月31日董事刘建凯减持股份合计8000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656371716?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:01","pubTimestamp":1785762085,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月3日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月31日公司董事,高管刘建凯共减持公司股份8000.0股，占公司总股本为0.0007%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出861.35万，融资余额减少；融券净流入5.24万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300034673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655087369","title":"康泰生物：7月30日董事刘建凯减持股份合计5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655087369","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655087369?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:01","pubTimestamp":1785502884,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月31日市场公开信息、上市公司公告及交易所披露数据整理，康泰生物最新董监高及相关人员股份变动情况：2026年7月30日公司董事,高管刘建凯共减持公司股份5000.0股，占公司总股本为0.0004%。康泰生物近半年内的董监高及核心技术人员增减持详情如下：康泰生物的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出907.8万，融资余额减少；融券净流入6500.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100039679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790344093071,"stockEarnings":[{"period":"1week","weight":0.0943},{"period":"1month","weight":-0.0054},{"period":"3month","weight":0.1741},{"period":"6month","weight":-0.0719},{"period":"1year","weight":-0.2329},{"period":"ytd","weight":-0.1254}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":-0.0003},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"60876人(较上一季度减少1.68%)","perCapita":"14790股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111693万元","survey":"　　深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。近年来，康泰生物荣获国家企业技术中心、国家技术发明奖二等奖、广东省预防医学会科技进步奖特等奖、深圳市科技进步奖一等奖、中国生物医药企业20强等多项殊荣，在传染病预防领域创造的社会价值及经济效益得到社会各界普遍认可。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}